'Superiority of drug over placebo was demonstrated in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), which was one of the exploratory efficacy measures in the INTREPID trial. RBANS is a validated series of tests completed by the patient for assessing cognitive impairment that is commonly used in the diagnosis and tracking of dementia.'
Have we got a potential demetia drug here?
Dementia
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.30 |
Change
-0.200(1.03%) |
Mkt cap ! $2.466B | |||
| Open | High | Low | Value | Volume |
| $19.50 | $19.59 | $19.11 | $5.729M | 296.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 259 | $19.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 640 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |